

Nifty Futures	Level 1	Level 2	Level 3
Resistance	10300	10340	10400
Support	10240	10180	10150

Indices (NSE)	Close	Pts. Chg	% Chg
Nifty	10,283.6	68.9	0.7
Nifty Future (Oct)	10,308.9	58.0	0.6
Nifty Future (Nov)	10,345.9	59.4	0.6
Bank Nifty	25,728.4	281.8	1.1
CNX100	10,701.3	82.8	0.8
CNX500	9,137.1	72.1	0.8
CNX Midcap	19,642.6	201.7	1.0

Indices (BSE)	Close	Pts. Chg	% Chg
Sensex	33,342.8	236.0	0.7
BSE-100	10,743.4	80.2	0.7
BSE-200	4,530.5	34.1	0.8
BSE-500	14,454.3	110.3	0.8
Mid Cap	16,673.3	169.3	1.0
Small Cap	17,605.1	142.3	0.8

Sectoral Indices	Close	Pts. Chg	% Chg
BANKEX	29,241.9	339.5	1.2
CAPITAL GOODS	18,236.0	82.1	0.5
REALTY	2,362.0	84.3	3.6
POWER	2,271.8	16.7	0.7
OIL & GAS	15,714.9	52.8	0.3
METAL	14,248.6	251.5	1.8
CD	20,336.2	293.9	1.5
AUTO	25,069.8	193.8	0.8
TECK	6,064.9	-67.6	-1.1
IT	10,732.4	-150.3	-1.4
FMCG	10,260.5	70.3	0.7
HEALTHCARE	13,742.5	140.5	1.0
VIX	13.7	0.3	1.9

Exchange	Advance	Decline	Unchg
BSE	1,615	1,135	178
NSE	1,106	628	91

Volume	Rs (in cr)	% Chg
NSE Cash	36,807.3	27
BSE Cash	4,675.9	20
NSE F&O	533,733.2	-48

Net Inflows/Outflows (Rs in cr)	Buy	Sell	Net
FII	6,715.9	5,439.3	1,276.6
DII	4,377.7	2,910.8	1,466.9

Intraday Nifty Outlook

Index opened gap up but failed to sustain the gains and giveback most of the gains. Earlier Index has given breakout from the consolidation in which it was moving for past over two months which is a bullish signal for medium term trend. Going ahead index has immediate support at 10230-10180, till it maintains above this level it is expected to continue its up move towards 10340-10400 while support past 10180 comes at 10090.

Corporate News

SAIL to diversify product range

State-run Steel Authority of India Ltd (SAIL) is looking to diversify its product basket through value-added and ready-to-use product offerings. Plans are also afoot to scale up its presence in global markets by venturing into newer markets, said a press statement issued by the company. According to PK Singh, Chairman, with its new and modernised mills stabilising, the company will look at diversifying its product basket with several value-added and ready-to-use products. "We will introduce several new and niche brands to the product basket. Gauging the domestic and international market, we aim to have a blend of both markets in our portfolio," Singh said, during his interaction with the marketing team and employees of SAIL in Kolkata. Talking about scaling up presence in global markets, he said close to 10 per cent of its saleable steel production will be targeted for new markets overseas, including Africa, Philippines, Indonesia, Thailand, Sri Lanka and Bangladesh. SAIL will also be streamlining its channel management to address the needs of customers in untapped geographies. "In the times to come, we will focus on retail sales with higher volumes and deeper reach along with exploring effective ways of transportation and logistics," he said. He also identified consolidation of its market leadership as a crucial tool for the turnaround of the company. (Source: Business Line)

Eris Lifesciences buys Strides' branded generic biz for Rs. 500 cr

A move that will strengthen the position of the Ahmedabad-based Eris Lifesciences Limited in the Central Nervous System (CNS) segment, the company on Saturday announced signing of a definitive agreement with Strides Shasun Limited to acquire its branded generics business. The deal - likely to be closed in two weeks - is estimated at around Rs. 500 crore. To be funded by a mix of internal accruals and debt, the acquisition - fourth and the largest in 18 months - will put Eris among the top ten companies in the CNS segment. Eris, having a market cap of Rs.8045 crore as on November 17, already has strong presence in the cardiology segment and ranks among the top ten in the diabetology segment. Strides' India branded generics business comprise of a portfolio of over 130 brands in the domains of Neurology, Psychiatry, Nutraceuticals, Gastro etc. along with the employees forming part of the business. As per the terms of agreement, Eris will acquire the marketing and distribution rights for the said portfolio of products in India while Strides will retain the global rights for these products. The decision came after the company's board meeting held on Saturday. Post-acquisition Eris will break into the league of top 25 companies having a market share of more than 1 per cent in the Indian Pharmaceutical Market. "There is a lot of synergy in the portfolio. This portfolio will propel us well in the CNS portfolio, which is the third largest and one of the most attractive because of the aging population. This acquisition Will make the company one of the significant players in the CNS segment," Amit Bakshi, Managing Director Eris Lifesciences Limited told Businessline. In Company's CNS portfolio, there are 10 -15 brands, with a total size of the portfolio of about Rs. 50-60 crore as per the last year's calculations. Company's flagship brand - Reverse itself is worth Rs. 70 crore. (Source: Business Line)

L&T Construction bags Rs 8,650-cr order from MMRDA

Larsen & Toubro (L&T) today said its construction arm has bagged a Rs 8,650-crore order from the Mumbai Metropolitan Region Development Authority (MMRDA). The heavy civil infrastructure business vertical of L&T Construction bagged an order worth Rs 8,650 crore from the MMRDA for construction of the Mumbai Trans Harbour Link, the engineering and construction major said in a BSE filing. The project involves construction of 21.8-km bridge connecting the Mumbai mainland with Navi Mumbai. "The proposed Mumbai Trans Harbour Link will serve as an economic gateway to Navi Mumbai, connecting to Nhava Sheva Port, the Mumbai Pune Expressway and the Mumbai Goa highway," it added. (Source: Business Line)



Morning Wealth

Nifty Top 5 Gainers	Close	Pts. Chg	% Chg
CIPLA	608.6	15.7	2.7
HDFC	1705.5	41.1	2.5
MARUTI	8348.4	184.7	2.3
TATASTEEL	701.2	14.9	2.2
VEDL	307.6	6.3	2.1

Nifty Top 5 Losers	Close	Pts. Chg	% Chg
TECHM	484.6	-15.4	-3.1
INFY	971.0	-17.4	-1.8
BOSCHLTD	18965.9	-292.5	-1.5
TCS	2707.3	-39.3	-1.4
HCLTECH	840.0	-11.9	-1.4

Int. Indices	Close	Pts. Chg	% Chg
S&P 500	2,578.9	-6.8	-0.3
DOW	23,358.2	-100.1	-0.4
NASDAQ	6,782.8	-10.5	-0.2
FTSE	7,380.7	-6.3	-0.1
DAX	12,993.7	-53.5	-0.4
CAC	5,319.2	-17.2	-0.3
NIKKEI	22,281.9	-115.0	-0.5
Hangseng	29,152.4	-46.7	-0.2
Straits Times	3,379.7	-2.7	-0.1

ADR	Close	Pts. Chg	% Chg
HDFC Bank	97.0	2.5	2.6
ICICI Bank	9.9	0.2	1.7
Infosys	15.2	-0.1	-0.5
TATA Motors	32.5	0.7	2.1
Wipro	5.3	0.0	0.2

Currencies	Close	Pts. Chg	% Chg
Dollar Index	94.0	0.4	0.4
USD/INR	65.0	-0.3	-0.5
EURO/INR	76.8	-0.1	-0.1
USD/YEN	112.0	0.0	0.0

Commodities	Close	Pts. Chg	% Chg
Gold (spot) Rs	29,690.0	187.0	0.6
Silver (spot) Rs	40,013.0	214.0	0.5
Crude (Brent) \$	62.6	-0.2	-0.3
Crude Oil (WTI) \$	56.6	0.1	0.1

Economy

India moves up one notch to 126 in terms of per capita GDP

India has moved up one position to 126th in terms of per capita GDP of countries, still ranked lower than all its BRICS peers, while Qatar remains the world's richest on this parameter. The IMF data, which forms part of the latest World Economic Outlook report of the International Monetary Fund, ranks over 200 countries in terms of per capita GDP based on purchasing power parity (PPP). PPP between two countries is the rate at which the currency of one country needs to be converted into that of a second country to ensure that a given amount of the first country's currency will purchase the same volume of goods and services in the second country as it does in the first. India has seen its per capita GDP rise to \$7,170 in 2017, from USD 6,690 last year, helping improve its rank by a position to 126th. Qatar remains top-ranked with per capita GDP of \$1,24,930, followed by Macao at the second position with \$1,14,430 and Luxembourg third with \$1,09,190. Among BRICS countries, India has the lowest per capita GDP. Russia boasts of a GDP per capita of \$27,900, while for China, it stood at \$16,620, Brazil at \$15,500 and South Africa at \$13,400. Interestingly, as per a recent Credit Suisse report, India is home to 2.45 lakh millionaires with a total household wealth of \$5 trillion. (Source: Business line)

International News

Euro Drops as German Talks Fail; Asian Stocks Slip

The euro declined after German Chancellor Angela Merkel's push to form a coalition government collapsed. Asian stocks resumed last week's slide in early trading Monday amid signs of fatigue following a stellar year for the region's equities. Shares fell in Japan and Sydney. Chinese equities extended Friday's slump triggered by state media warnings of stocks rising too fast. The dollar advanced against most G-10 counterparts, giving it a better start this week after dropping the past two. U.S. equities dropped on Friday, when the gap between two- and 10-year Treasury yields hit the tightest level in a decade, adding to concern about the pace of future economic growth. Bitcoin climbed to a fresh high, topping \$8,000. While the German political impasse triggered an immediate reaction, it occurs against the backdrop of a European economy that's expanding strongly enough that the European Central Bank is scaling back its stimulus program. Just Friday, European Central Bank President Mario Draghi helped boost the euro past \$1.18 with comments predicting that European wage gains will pick up. The euro came off its lows of the session as Asian trading progressed. "The news is negative for the euro, but its longer-term implications are not clear yet," said Mansoor Mohi-uddin, head of currency strategy in Singapore at NatWest Markets, a unit of Royal Bank of Scotland Group Plc. Meantime, the tilt away from stocks comes as investors try to gauge whether there are sufficient drivers to continue the march to historic highs. (Source: Bloomberg)

Major Bulk Deal (NSE)

Scrip Name	Qty	Type	Client Name	Trade Price
No Major Bulk Deals				

Major Bulk Deal (BSE)

Scrip Name	Qty	Type	Client Name	Trade Price
No Major Bulk Deals				



Morning Wealth

EVENTS CALENDAR

Monday	Tuesday	Wednesday	Thursday	Friday
<p>20-Nov-2017</p> <p>Results—</p> <p>Economic Indicators—</p> <p>US—</p>	<p>21-Nov-2017</p> <p>Results – Dixon,</p> <p>Economic Indicators –</p> <p>US—</p>	<p>22-Nov-2017</p> <p>Results -</p> <p>Economic Indicators—</p> <p>US– Jobless Claims</p>	<p>23-Nov-2017</p> <p>Results —</p> <p>Economic Indicators—</p> <p>US—</p>	<p>24-Nov-2017</p> <p>Results–</p> <p>Economic Indicators–</p> <p>US–</p>
<p>27-Nov-2017</p> <p>Results— Apollo Hospi- tal,</p> <p>Economic Indicators—</p> <p>US—</p>	<p>28-Nov-2017</p> <p>Results – Dixon,</p> <p>Economic Indicators –</p> <p>US—</p>	<p>29-Nov-2017</p> <p>Results -</p> <p>Economic Indicators—</p> <p>US—</p>	<p>30-Nov-2017</p> <p>Results —</p> <p>Economic Indicators— GDP Growth Rate</p> <p>US– Jobless Claims</p>	<p>01-Dec-2017</p> <p>Results–</p> <p>Economic Indicators–</p> <p>US–</p>
<p>4-Dec-2017</p> <p>Results—</p> <p>Economic Indicators—</p> <p>US—</p>	<p>5-Dec-2017</p> <p>Results –</p> <p>Economic Indicators –</p> <p>US—</p>	<p>6-Dec-2017</p> <p>Results -</p> <p>Economic Indicators—</p> <p>US—</p>	<p>7-Dec-2017</p> <p>Results —</p> <p>Economic Indicators—</p> <p>US– Jobless Claims</p>	<p>8-Dec-2017</p> <p>Results–</p> <p>Economic Indicators–</p> <p>US–</p>

Green: Corporate Event, Red: Economic Events, Dark Blue: US Events/ UK Events

(Source: Bloomberg and BSE)

**Disclaimer Appendix****Analyst (s) holding in the Stock : Nil****Analyst (s) Certification:**

We analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer (s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation (s) or view (s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the BP Equities Pvt. Ltd. (Institutional Equities).

General Disclaimer

This report has been prepared by the research department of BP EQUITIES Pvt. Ltd, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.

BP EQUITIES Pvt. Ltd have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice.

Recipients of this material should rely on their own investigations and take their own professional advice. BP EQUITIES Pvt. Ltd or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. BP EQUITIES Pvt. Ltd. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

BP EQUITIES Pvt. Ltd and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to BP EQUITIES Pvt. Ltd or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Corporate Office:

4th floor,
Rustom Bldg,
29, Veer Nariman Road, Fort,
Mumbai-400001
Phone- +91 22 6159 6464
Fax-+91 22 6159 6160
Website- www.bpwealth.com

Registered Office:

24/26, 1st Floor, Cama Building,
Dalal street, Fort,
Mumbai-400001
BP Wealth Management Pvt. Ltd.
CIN No: U67190MH2005PTC154591
BP Equities Pvt. Ltd.
CIN No: U67120MH1997PTC107392